Karran, E;
De Strooper, B;
(2016)
The amyloid cascade hypothesis: are we poised for success or failure?
Journal of Neurochemistry
, 139
pp. 237-252.
10.1111/jnc.13632.
Preview |
Text
De Strooper_PDF for UCL of The Amyloid Cascade Hypothesis Karran BDS.pdf - Accepted Version Download (704kB) | Preview |
Abstract
The first description of Alzheimer's disease (AD) was made in 1907 by Alois Alzheimer (Allgemeine Zeitschrift fur Psyciatrie und Psychisch-Gerichtliche Medizin 64, 3, 1907), although other contemporary physicians had made similar, and rather more complete, assessments of the neuropathological changes present in the AD brain (Fischer, Monatsschr Psychiat Neurol 22, 17, 1907). Our knowledge of AD has increased dramatically and continues to accelerate. This year is 25 years after the publication of a series of papers that, in various ways, articulated the amyloid cascade hypothesis (ACH) for AD (Beyreuther and Masters, Brain Pathol 1, 241–251, 1991; Hardy and Allsop, Trends Pharmacol Sci 12, 383–388, 1991; Selkoe, Neuron 6, 487–498, 1991; Hardy and Higgins, Science 256, 184–185, 1992). This review will cover some familiar territory, but we shall also place the ACH into a wider context, compare it with other hypotheses for AD, explore the evolution of the hypothesis to encompass new findings, and determine, irrespective of the merits of the hypothesis itself, whether it has been useful for the research field, both in academia and in industry. Finally, we shall review how the ACH has led to a number of therapeutic approaches, all of which have, to date, failed to reach their primary efficacy end-points in clinical trials and reflect upon what the future may hold. image We review the amyloid cascade hypothesis (ACH) and compare it with other hypotheses that have been posited to explain the initiation and progression Alzheimer's disease. We document the data that support the ACH, and also reflect upon its deficiencies. We list the recent clinical failures of amyloidocentric drugs and anticipate the results that new therapeutic approaches may deliver.
| Type: | Article |
|---|---|
| Title: | The amyloid cascade hypothesis: are we poised for success or failure? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/jnc.13632 |
| Publisher version: | http://dx.doi.org/10.1111/jnc.13632 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Biochemistry & Molecular Biology, Neurosciences, Neurosciences & Neurology, Alzheimer's disease, Amyloid cascade clinical development, FAMILIAL ALZHEIMERS-DISEASE, A-BETA OLIGOMERS, GAMMA-SECRETASE ACTIVITY, AGE-OF-ONSET, PRECURSOR PROTEIN, APOLIPOPROTEIN-E, IN-VIVO, COGNITIVE DECLINE, ASPARTYL PROTEASE, TRANSGENIC MOUSE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UK Dementia Research Institute HQ |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1542125 |
Archive Staff Only
 |
View Item |
